Therapeutics & Diagnostics

CCI has a robust pipeline of TxDx technologies, due in part to Cleveland Clinic’s world- class Lerner Research Institute. CCI works closely with all investigators to translate their findings into a marketable product or compound.
 
Anti-CEP Therapeutic for Age Related Macular Degeneration

Anti-CEP Therapeutic for Age Related Macular Degeneration

This is a HIA partner technology

John W. Crabb, PhD; Robert G. Salomon, PhD; Bela Anand-Apte, MD, PhD; Quteba Ebrahem, MD; Kutralanathan Regnathan

Wet macular degeneration is the advanced stage of age-related macular degeneration (AMD) and affects approximately 10-15% of patients with AMD, yet accounts for more than 80% of all vision loss associated with the disease. Wet AMD is caused by abnormal blood vessel growth in the retina, known as choroidal neovascularization.


Application of Mitotic Kinesin Targeting Strategies to the Treatment of Anaplastic Gliomas

Application of Mitotic Kinesin Targeting Strategies to the Treatment of Anaplastic Gliomas

This is a HIA partner technology

Steven Rosenfeld, MD, PhD; Jeremy Rich, MD; Monica Venere, PhD

Mitotic kinesins are motor proteins required to facilitate proper cell division (mitosis).  Recent studies by Dr. Rosenfeld and his team have shown that one of these kinesins, Eg5, is up-regulated in tumor cells from human glioblastomas. 


Aptamers for Tumor Initiating Cells

Aptamers for Tumor Initiating Cells

This is a HIA partner technology

Jeremy Rich, MD; Youngmi Kim; Anita Hjelmeland, PhD

Aptamers are oligonucleotide or peptide molecules that bind to a specific target molecule.  Dr. Rich and his team have developed aptamers consisting of a single stranded nucleic acids having 100 nucleotides or less that specifically binds to tumor initiating cancer cells, identified by screening a large pool of randomly generated aptamers to obtain a discrete set of them that specifically bind to tumor initiating cancer cells, such as those found in brain cancer or glioblastoma.


Autologous C5 Vaccines For Treating Complement-Mediated Diseases

Autologous C5 Vaccines For Treating Complement-Mediated Diseases

This is a HIA partner technology

Feng Lin, PhD; M.G. Finn, PhD

The complement system is emerging as a new target for treating many diseases. For example, Eculizumab, a humanized monoclonal antibody against complement component 5 (C5), has been approved for paroxysmal nocturnal hemoglobinuria (PNH) in which patient erythrocytes are lysed by complement.


CCMCL 1: A New Model of Aggressive Mantle Cell Lymphoma

CCMCL 1: A New Model of Aggressive Mantle Cell Lymphoma

This is a HIA partner technology

Eric Hsi, MD

Mantle cell lymphoma (MCL) is incurable using current standard therapeutic regimens. Additionally, there are relatively few cell lines and mouse models to support drug discovery and development efforts.


Composition and Methods for Sensitizing Androgen Receptor Positive Breast Cancers to Radiation

Composition and Methods for Sensitizing Androgen Receptor Positive Breast Cancers to Radiation

This is a HIA partner technology

Mohamed Abazeed, MD, PhD

Integration of high-throughput radiation survival profiling with large-scale cancer genomic data suggests AR expression is associated with therapeutic resistance in breast cancer. Our analysis nominates anti-androgen therapies, which are commercially available and currently in clinical use in prostate and breast cancer, as therapeutic sensitizers in select AR positive breast cancer.


Genetic Mechanism Augments DHT Synthesis in CRPC

Genetic Mechanism Augments DHT Synthesis in CRPC

This is a HIA partner technology

Nima Sharifi, MD

The technology is a diagnostic tool that assesses an actionable biomarker for treatment selection in the prostate cancer care continuum.


Humanized Anti-CD6 mAb for Treating of Autoimmune Diseases

Humanized Anti-CD6 mAb for Treating of Autoimmune Diseases

This is a HIA partner technology

Feng Lin, PhD

Dr. Lin's research suggests that targeting CD6 gene is a promising effective treatment for Multiple Sclerosis.


In-vitro Platform for Drug Identification, Selection and Prioritization Toward Preclinical and Clinical Development

In-vitro Platform for Drug Identification, Selection and Prioritization Toward Preclinical and Clinical Development

This is a HIA partner technology

Frederic Reu, MD

Despite progress, multiple myeloma remains largely incurable, recruiting relapses from genetically heterogeneous multiple myeloma subclones.


Localized Therapy of PSMA Expressing Tumors Utilizing a Radiolabeled PSMA Targeting Tracer

Localized Therapy of PSMA Expressing Tumors Utilizing a Radiolabeled PSMA Targeting Tracer

This is a HIA partner technology

Steve Shih Lin Huang, MD, PhD

Researchers at Cleveland Clinic have developed peptide tracers that target prostate specific membrane antigen (PSMA).


Previous 1 2 3 Next 
 

Get In Touch With Us